Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

White Matter Hyperintensities in Aging and Dementia

Trial Profile

White Matter Hyperintensities in Aging and Dementia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Pharmacodynamics
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 Nov 2019.
    • 18 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Nov 2019.
    • 18 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top